DrJMW said:
DECA gyno is brought on by an increase in prolactin levels. The latent duct tissue "wakes up" and starts producing lactose. This is different from estrogenic gyno, but both are unpleasant in males.
I disagree:
Journal of Clinical Endocrinology and Metabolism
Copyright Q 1993 by The Endocrine Society
Vol. 16, No. 4
Ingestion of Androgenic-Anabolic Steroids Induces Mild Thyroidal Impairment in Male Body Builders
ROMAN DEYSSIG AND MICHAEL WEISSEL
Third Medical University Clinic and L. Boltzmann Institute for Nuclear Medicine, A-1090 Vienna, Austria
Thirteen bodybuilders, recruited in local training centers, with normal thyroid function were investigated. Thyroid dysfunction was excluded by measurement of free Td, palpation of the thyroid, and clinical investigation. All athletes performed regular strength training up to six times a week. Five of the athletes admitted self administration of androgenic-anabolic steroids. These were obtained from nonmedical sources. The start of steroid intake was at least 6 weeks before the study. The individual doses of their self-reported “stacking regimen” (two or more different steroids simultaneously; see Ref. 12) were as follows. Testosterone was used im once or twice a week in different esters, such as
propionate, phenylpropionate, capronate, isocaprionate, and enantate.
Nandrolone (17@-hydroxy-4-e&en-3-one) was injected once a week as phenylpropionate or decanoate....
Tables 2 and 3 give the mean values and SES of the serum hormone concentrations in both groups. Basal TBG, total Ts,
and total T4 were significantly lower in the group of athletes taking steroids (Table 2), with
no significant difference in free Td, TSH, and PRL between the two groups.
Basal and stimulated PRL levels were unaffected by androgens, as has been described previously for pharmaco-logical doses in hypogonadal men (10).
---------------------
OK, this one is not the best example:
Clin Nephrol 1989 Oct;32(4):198-201 Related Articles, Links
Anabolic steroid-associated hypogonadism in male hemodialysis patients.
Maeda Y, Nakanishi T, Ozawa K, Kijima Y, Nakayama I, Shoji T, Sasaoka T.
Dialysis Center, Yokosuka Kyosai Hospital, Kanagawa, Japan.
Hypogonadism in male hemodialysis patients has been previously reported. However, its precise pathogenesis has not yet been clarified. Mepitiostane and nandrolone decanoate are anabolic steroids prescribed for uremic anemia, and those may possibly exacerbate uremic gonadal damage. We studied the influences of these steroids on male gonadal function. Seventy-six hemodialysis patients were selected and examined for levels of luteinizing hormone (LH), follicular stimulating hormone (FSH), total testosterone, and prolactin. Twenty-three patients who received anabolic steroids showed lower testosterone values (205.2 +/- 35.6 ng/dl) than did patients without these steroids (449.7 +/- 21.3 ng/dl). Gonadotropins and prolactin showed no significant differences between the patients with and without the steroids. The testosterone values of three patients with mepitiostane increased after they stopped taking steroids. One patient suffering from complete aspermia recovered (sperm count: 0/ml to 1300 x 10(4)/ml) after discontinuation of mepitiostane and administration of human chorionic gonadotropin (HCG). This clinical study suggests that some anabolic steroids play a role in uremic hypogonadism; thus mepitiostane or its analogues should be carefully prescribed for young male patients.
.
